NotesClinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem
References (12)
- et al.
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999–2005)
Diagn. Microb. Infect. Dis.
(2006) - et al.
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae
J. Clin. Microbiol.
(2007) - et al.
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City
Clin. Infect. Dis.
(2004) - et al.
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium
Arch. Intern. Med.
(2005) - et al.
Detection of Klebsiella pneumoniae carbapenemase (KPC) by Vitek 2 AST GN Card using ertapenem as the indicator
- et al.
APACHE II: a severity of disease classification system
Crit. Care Med.
(1985)
There are more references available in the full text version of this article.
Cited by (98)
Assessment of mortality stratified by meropenem minimum inhibitory concentration in patients with Enterobacteriaceae bacteraemia: A patient-level analysis of published data
2020, International Journal of Antimicrobial AgentsCarbapenem-resistant Enterobacteriaceae: An emerging bacterial threat
2019, Seminars in Diagnostic PathologyPrevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China
2024, Emerging Microbes and Infections
- 1
Authors contributed equally to the work.
Copyright © 2009 Elsevier Inc. All rights reserved.